Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been in and out of this stock for a while. With lawsuits looming cash burning it was channeling in the 50s give or take. But with this news, law suits over, many other positives, I bought back in at .75. Totally up to u but I don't think there is any reason for NVCN to drop. Most people either scalped today or sold for profits early morning. Good luck Go NVCN
Red to green baby
.08 by turkey day
If we can blow thru these 9s it looks like take off time
Lookin great
Doesn't sound good to me either but with this over now a buyout is way more likely
Agree. Selling within a week is a mistake
Haha. Thanks
I don't blame ya. Just want someone to light the wick on this b
Bid sitters cmon man
Early in the day but looks like presentation went well yesterday
People will be chasing tommorow
We have a lot more to go before I even contemplate selling this beautiful little gem
I did. Originally on my finviz or schwab or scottrade, one said the 29th but not anymore
What do you think, shorts covering before fins and updates?
I sold after the ride up a month ago but just re entered with fins coming out, schwab said 8/4 and the website I posted said 7/29 both before market opens. I am hopeful that we will start hearing more from the company throughout August or even next week.
Neovasc Inc.’s (NVCN) is expected to announce its next earnings on 7/29/2016 8:30:00 AM. EPS growth for this year is -19.20% and EPS growth for next year is expected to reach at 25.80%.
http://www.isstories.com/healthcare-stock-latest-update-neovasc-inc-s-nvcn/8723738/
I'm enjoying gobbling up these mid 40s.
Buy the fear!!!!!!!!
Skip to main page content
FDA
U.S. Food and Drug Administration
Search FDA Submit search
Popular Content
News & Events
New and Generic Drug Approvals
SHARE
TWEET
MORE SHARING OPTIONS
EMAIL
July 13, 2016
Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
Isoniazid isoniazid Tablet;Oral Sandoz Labeling Revision
Morphine Sulfate morphine sulfate Solution;Oral Rhodes Pharms Approval
Rozerem ramelteon Tablet;Oral Takeda Pharms Usa Manufacturing Change or Addition
Smoflipid soybean;mct;olive;fish Injectable, Lipid Complex;Injection Fresenius Kabi Usa Approval
Thallous Chloride Tl 201 thallous chloride tl-201 Injectable;Injection Mallinkrodt Nuclear Labeling Revision
July 12, 2016
Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
Amlodipine Besylate amlodipine besylate Tablet;Oral Polygen Pharms Approval
Asmanex Hfa mometasone furoate Aerosol, Metered;Inhalation Merck Sharp Dohme Efficacy Supplement with Clinical Data to Support
Cialis tadalafil Tablet;Oral Lilly Manufacturing Change or Addition
Cymbalta duloxetine hydrochloride Capsule, Delayed Rel Pellets;Oral Lilly Manufacturing Change or Addition
Dulera formoterol fumarate; mometasone furoate Aerosol, Metered;Inhalation Merck Sharp Dohme Efficacy Supplement with Clinical Data to Support
Effient prasugrel hydrochloride Tablet;Oral Eli Lilly and Co Efficacy Supplement with Clinical Data to Support
Faslodex fulvestrant Injectable;Intramuscular Astrazeneca Labeling Revision
Fenofibrate fenofibrate Tablet;Oral Hetero Labs Ltd Iii Approval
Tarka trandolapril; verapamil hydrochloride Tablet, Extended Release;Oral Abbvie Labeling Revision
July 11, 2016
Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
Alinia nitazoxanide Tablet;Oral Romark Labeling Revision
Alinia nitazoxanide For Suspension;Oral Romark Labeling Revision
Brovana arformoterol tartrate Solution;Inhalation Sunovion Manufacturing Change or Addition
Furadantin nitrofurantoin Suspension;Oral Shionogi Inc Manufacturing Change or Addition
Gatifloxacin gatifloxacin Solution/Drops;Ophthalmic Alcon Res Ltd Approval
Juxtapid lomitapide mesylate Capsule;Oral Aegerion Manufacturing Change or Addition
Metformin Hydrochloride metformin hydrochloride Tablet;Oral Cspc Ouyi Pharm Co Approval
Vilazodone Hydrochloride vilazodone hydrochloride Tablet;Oral Teva Pharms Usa Tentative Approval
Xiidra lifitegrast Solution/Drops; Ophthalmic Shire Dev Llc Approval
July 8, 2016
Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
Absorica isotretinoin Capsule;Oral Ranbaxy Supplement
Azor amlodipine besylate; olmesartan medoxomil Tablet;Oral Daiichi Sankyo Manufacturing Change or Addition
Benicar olmesartan medoxomil Tablet;Oral Daiichi Sankyo Manufacturing Change or Addition
Dexilant dexlansoprazole Capsule, Delayed Release;Oral Takeda Pharms Usa Efficacy Supplement with Clinical Data to Support
Dexilant Solutab dexlansoprazole Tablet, Orally Disintegrating, Delayed Release;Oral Takeda Pharms Usa Labeling Revision
Differin adapalene Gel;Topical Galderma Labs Lp Efficacy Supplement with Clinical Data to Support
Duexis famotidine; ibuprofen Tablet;Oral Horizon Pharma Manufacturing Change or Addition
Femcon Fe ethinyl estradiol; norethindrone Tablet, Chewable;Oral Apil Manufacturing Change or Addition
Glyxambi empagliflozin; linagliptin Tablet;Oral Boehringer Ingelheim Labeling Revision
Hicon sodium iodide i-131 Solution;Oral Jubilant Draximage Labeling Revision
Humulin R insulin human Solution;Subcutaneous Lilly Labeling Revision
Humulin R insulin recombinant human Injectable;Injection Lilly Labeling Revision
Humulin R Kwikpen insulin human Solution;Subcutaneous Lilly Labeling Revision
Humulin R Pen insulin recombinant human Injectable;Injection Lilly Labeling Revision
Idkit:hp citric acid; urea c-13 For Solution, Tablet, For Solution;Oral Exalenz Bioscience Manufacturing Change or Addition
Jardiance empagliflozin Tablet;Oral Boehringer Ingelheim Labeling Revision
Lamprene clofazimine Capsule;Oral Novartis Labeling Revision
Latuda lurasidone hydrochloride Tablet;Oral Sunovion Pharms Inc Manufacturing Change or Addition
Lyrica pregabalin Capsule;Oral Pf Prism Cv Manufacturing Change or Addition
Menopur menotropins (fsh;lh) Injectable;Subcutaneous Ferring Manufacturing Change or Addition
Omidria ketorolac tromethamine; phenylephrine hydrochloride Solution;Irrigation Omeros Manufacturing Change or Addition
Pentetate Calcium Trisodium pentetate calcium trisodium Solution;Inhalation, Intravenous Hameln Pharma Plus Manufacturing Change or Addition
Repatha evolocumab Injectable;Injection Amgen Inc Efficacy Supplement with Clinical Data to Support
Repatha evolocumab Injectable;Injection Amgen Inc Labeling Revision
Sodium Iodide I 131 sodium iodide i-131 Capsule;Oral Jubilant Draximage Labeling Revision
Synjardy empagliflozin; metformin hydrochloride Tablet;Oral Boehringer Ingelheim Efficacy Supplement with Clinical Data to Support
Synjardy empagliflozin; metformin hydrochloride Tablet;Oral Boehringer Ingelheim Labeling Revision
Tegretol carbamazepine Suspension;Oral Novartis Manufacturing Change or Addition
Tresiba insulin degludec Solution;Subcutaneous Novo Nordisk Inc Manufacturing Change or Addition
Veregen sinecatechins Ointment;Topical Medigene Ag Manufacturing Change or Addition
July 7, 2016
Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
Bunavail buprenorphine hydrochloride; naloxone hydrochloride Film;Buccal Biodelivery Sci Intl Supplement
Cerezyme imiglucerase Injectable;Injection Genzyme Manufacturing Change or Addition
Hydromorphone Hydrochloride hydromorphone hydrochloride Tablet, Extended Release;Oral Osmotica Approval
Intuniv guanfacine hydrochloride Tablet, Extended Release;Oral Shire Labeling Revision
Mili ethinyl estradiol; norgestimate Tablet;Oral-28 Aurobindo Pharma Ltd Approval
Suboxone buprenorphine hydrochloride; naloxone hydrochloride Tablet;Sublingual Indivior Inc Supplement
Suboxone buprenorphine hydrochloride; naloxone hydrochloride Film;Buccal, Sublingual Indivior Inc Supplement
Subutex buprenorphine hydrochloride Tablet;Sublingual Indivior Inc Supplement
Triamcinolone Acetonide triamcinolone acetonide Lotion;Topical Teligent Pharma Inc Approval
Triamcinolone Acetonide triamcinolone acetonide Lotion;Topical Teligent Pharma Inc Approval
Zubsolv buprenorphine hydrochloride; naloxone hydrochloride Tablet;Sublingual Orexo Ab Supplement
More in News & Events
CDER Conversations
Director's Corner Podcasts
From our perspective
Transcript: Director’s Corner Podcast – Dr. Woodcock celebrates 30 years at FDA
Resources for You
New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products
What's New Related to Drugs
Hematology/Oncology (Cancer) Approvals & Safety Notifications
Meetings, Conferences, & Workshops (Drugs)
Page Last Updated: 07/14/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Accessibility
Website Policies
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
1-888-INFO-FDA (1-888-463-6332)
Contact FDA
Subscribe to FDA RSS feeds Follow FDA on Twitter Follow FDA on Facebook View FDA videos on YouTube View FDA photos on Flickr
Scroll back to top
I bet we close w HOD
Exactly!!
Thank u
Why people are selling so low is beyond me. This company has a lot going for it with the Tiara and Reducer. A little good news and the chase will be on
I hope we squeeze them shorties
Locked n loaded
Hoping by Friday
Let's test 1.98 today
Holy Crap!! Just checked.
I anticipate positive news from the conferences this week that will boost shareholder confidence and get NVCN above the .50 mark
Yes. In a few accounts. About .42 average.
Neovasc Inc. (NASDAQ:NVCN) 6/11/16
Last Trade: The Company closed its last session at $0.4 with the loss of -5.84%. The market capitalization of the company is $28.61 Million, with the average Volume of 581.53K. The stock currently has its 52-Week High range of $7.63 and 52-week low range of $0.37. The Price to Sales (P/S) of the company is 2.97 whereas, P/B (Price to Book) stands at 0.56. By looking at the Volatility of the company, Week Volatility is at 20.08% and Month Volatility is at 19.89%.
According to 2 analysts, the Average Revenue Estimate of the current Fiscal quarter is $3.15 Million and according to them, the Low Revenue estimate is $2.88 Million and High Revenue estimate is $3.41 Million.
Neovasc Inc. (NVCN) currently has High Price Target of $9.25. The Low and Mean Price Targets are $5 and $7.09 respectively. These price targets are a consensus analysis of 3 brokers.
When having a look at Recommendation Trends of the stock polled by Thomson First call. For the Current month, 2 analysts have assigned this stock as Strong Buy where 1 assigned Buy, 0 analysts believe it’s a Hold, 0 said Underperform and 0 assigned Sell rating.
Thanks for the info.
What exactly is that PR saying